University of Antwerp Researcher Awarded €1 Million for Charcot-Marie-Tooth Disease Research
Prof. Dr. Albena Jordanova, a researcher at the VIB Center for Molecular Neurology at the University of Antwerp, has been awarded the prestigious Generet Prize for rare diseases. The €1 million prize, managed by the King Baudouin Foundation, will accelerate her work on Charcot-Marie-Tooth disease (CMT).
Understanding Rare Diseases and CMT
Rare diseases, affecting less than one in 2,000 people, impact a significant number of individuals. In Belgium alone, over 6,000 pathologies are identified, affecting more than 700,000 people King Baudouin Foundation. Often, patients face delays in diagnosis and limited treatment options.
CMT is the most common inherited neuropathy of the peripheral nervous system, with an estimated prevalence of 1 in 2,000 VIB Center for Molecular Neurology. This condition causes progressive degeneration of peripheral nerves, leading to muscle weakness and reduced sensitivity to touch and temperature. Symptoms can begin in childhood and may eventually result in significant mobility limitations, skeletal deformities, chronic pain and fatigue. While CMT doesn’t typically affect life expectancy, it often requires adjustments to quality of life VIB Center for Molecular Neurology.
Focus on a Rare Form of CMT
Prof. Dr. Jordanova’s research centers on a particularly rare form of CMT, found in only six families worldwide, linked to mutations in the YARS gene, which encodes tyrosyl-tRNA synthetase. This protein is crucial for the function of all cells. A key scientific question is why mutations in this widespread protein specifically affect peripheral neurons and cause a late-onset disease VIB Center for Molecular Neurology.
Her work involves studying affected families across generations and analyzing their genetic material to understand the disease’s development and the variations in its presentation. Patients and their families are eager for insights into the disease’s origins, progression, and potential therapies. “Knowing that we can help better understand the different forms of CMT and test possible treatments gives us hope, for our family and for future generations,” says Carole Haislip, a CMT patient VIB Center for Molecular Neurology.
Funding to Advance Research and Collaboration
The €1 million in funding will be used to decipher the biological mechanisms driving nerve degeneration, accelerate the testing of potential treatments, and foster international collaborations between clinicians, researchers, and patient organizations VIB Center for Molecular Neurology.
The Generet Fund, in partnership with the FRS-FNRS and an international jury, aims to establish this annual prize as a catalyst for rare disease research in Belgium King Baudouin Foundation.
Aminoacyl-tRNA Synthetase and CMT
Research has linked dominant intermediate Charcot-Marie-Tooth neuropathy subtype C (DI-CMTC) to mutations in the YARS gene, which encodes tyrosyl-tRNA synthetase PubMed. Studies have shown variations in the age of onset and disease progression between families with these mutations PubMed. Nerve conduction studies and sural nerve biopsies provide valuable diagnostic information and reveal patterns of axonal degeneration PubMed.
Keep reading